Tiba is a preclinical stage MIT venture developing RNA medicines based on a novel biodegradable nanoparticle delivery technology. Our proprietary delivery system is based on ionizable aminoalkyl branched lipidoids (the RNABL platform) that compact large RNA cargoes into stable nanoparticles compatible with multiple routes of administration. The RNABL system exhibits greater safety and potency than current lipid nanoparticles (LNPs). Our early expertise in developing RNA vaccines against infectious diseases led to a number of government grants and Tiba's membership in the Blue Knight program, a BARDA-JnJ consortium focused on medical countermeasures. Tiba was recently awarded a BARDA EZ-BAA contract to develop a lung-targeted therapeutic against influenza. With an established pipeline of infectious disease vaccines funded by external groups, Tiba is expanding into high-value therapeutic areas using the RNABL technology to address challenges in immuno-oncology and cardiovascular disease.